Found 116 articles
Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the enrollment and dosing of more than 100 subjects in the Company’s ongoing Phase 2/3 study of Tempol for the treatment of COVID-19.
Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (FDA) for Tempol for the treatment and prevention of COVID-19.
Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™Drug overdoses are the leading cause of death for those under age 50
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of naloxone hydrochloride that is included in the company’s ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product.
Adamis Pharmaceuticals Corporation announced that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the company that based on the company’s filing of its Quarterly Reports on Form 10-Q for the periods ended March 31, 2021, June 30, 2021 and September 30, 2021.
Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate UpdateManagement to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced financial results for the nine months ended September 30, 2021 and provided a business update.
Adamis Pharmaceuticals Corporation today announced that it will host an investor conference call on Monday, November 22, 2021 at 2 p.m. Pacific Time to discuss its financial and operating results for the first nine months of 2021, as well as provide a business update.
Mid-November is a relatively quiet period for the U.S. Food and Drug Administration in terms of its scheduled PDUFA dates. Read on for more.
Zimhi is indicated for use in both adults and children in the event of an emergency. It is to be given right away and does not take the place of emergency care.
Adamis Receives FDA Approval for ZIMHINew High-Dose Naloxone Product for the Treatment of Opioid Overdose
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis’ ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product.
Adamis Pharmaceuticals Corporation announced the appointment of Meera J. Desai, Ph.D., as a new director and member of the company’s board of directors.
Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection.
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that David C. Benedicto, who has been serving as the Company’s Chief Accounting Officer, will succeed Robert O. Hopkins as Chief Financial Officer, effective immediately.
Adamis Pharmaceuticals Announces a Publication with the Human Immune Monitoring Center at Stanford Demonstrating Tempol Significantly Inhibited Multiple Cytokines from COVID-19 Patient’s Cells
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced a publication in the peer reviewed journal, Clinical Immunology, entitled “Tempol, a novel antioxidant, inhibits both activated T cell and APC (Antigen Presenting Cell) derived cytokines in-vitro from COVID-19 patients."
Adamis Highlights National Institutes of Health (NIH) Article Entitled, “Tempol: A Potential Home Treatment for COVID-19”NIH Researchers Contend that Tempol can be taken orally and may stop the replication of the virus that causes COVID-19
Adamis Pharmaceuticals Corporation ) today highlighted that the NIH has identified Tempol as a potential home treatment for COVID-19
Adamis Pharmaceuticals Corporation announced that it has entered into a definitive agreement to sell a significant portion of the assets of its subsidiary, US Compounding Inc., related to USC’s human compounding pharmaceutical business and customers, in exchange for total gross consideration estimated to be up to $15 million before transaction fees and expenses.
Based on Results Provided by the Inspector of Election, Stockholders Re-Elected All Five Members of the Company's Board of Directors
Adamis Urges Stockholders to Vote to Reelect the Company’s Board of Directors at Upcoming Annual Meeting on Friday, July 16th
Adamis Pharmaceuticals Corporation urged its valued stockholders to vote to reelect all five members of the Company’s Board of Directors at the upcoming Annual Meeting of Stockholders on July 16, 2021.
Adamis Sends Letter to Stockholders to Address Jerald A. Hammann’s Costly, Distracting and Misguided Campaign
Adamis Pharmaceuticals Corporation today issued the below letter to stockholders.
Adamis has sent a letter to stockholders urging them to re-elect all the five board members as part of a strategic move to continue and maintain its current growth initiatives.
Adamis Sends Letter to Stockholders Regarding Its Strategic Focus on Tempol as a Potentially Potent Treatment for COVID-19
The Board of Directors appreciates your continued investment in Adamis Pharmaceuticals Corporation. Ahead of our Annual Meeting of Stockholders on July 16th, we want to once again urge you to vote to re-elect all five members of the Board.